Detalhe da pesquisa
1.
A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age.
Lancet Reg Health West Pac
; 24: 100484, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35664443
2.
Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose.
NPJ Vaccines
; 7(1): 12, 2022 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35087084